What Valette Treats: Main Uses and Benefits

The therapeutic uses of this combination, dienogest and ethinylestradiol, relate to various aspects of reproductive and hormonal health.

Primary Therapeutic Benefit: Pregnancy Prevention

The medicine is applied across domains where additional symptomatic support is needed in the domain of reproductive health management, providing support for long-term, reversible contraception for women of reproductive age. Its primary therapeutic benefit is applied in addressing the primary objective of pregnancy prevention, and it assists with maintaining functional stability.

Management of Symptom Clusters

The combination is commonly used to help with symptomatic relief for clinical presentations linked to hyperandrogenism and is applied in addressing distressing menstrual cycle symptoms. The conditions in which this combination is commonly used include the prevention of pregnancy, the management of mild to moderate acne vulgaris in women who require an oral contraceptive, and the relief of symptoms like dysmenorrhea (painful periods) and heavy menstrual bleeding.

This combination assists with maintaining functional stability, which supports patients during episodes of heightened discomfort and contributes to easing the overall symptom load related to both skin and gynaecological manifestations.

Quick Fact: Relief for Androgen-Related Symptoms The formulation is applied in settings where symptoms related to greasy skin and greasy hair are present, helping to address these noticeable functional strains.

This section outlines the officially documented population eligibility and non-eligibility criteria for Valette (dienogest/ethinylestradiol) as defined by government regulatory agencies.

Eligibility Scope

Populations Who Must Not Use Valette (Contraindicated)

Use is strictly contraindicated for women with:

• A high risk of arterial or venous thrombotic diseases, including DVT, PE, hypercoagulopathies, or a history of stroke or heart attack.
• Cigarette smokers over age 35.
• Pregnancy or suspected pregnancy.
• Active Liver Disease or liver tumors (benign or malignant).
• Hormone-sensitive malignancies (e.g., breast cancer, current or history of).
• Uncontrolled Hypertension, Diabetes mellitus with vascular disease, or Migraine with focal neurological symptoms.

Interactions with other medicines and products

The co-administration of Valette (dienogest/ethinylestradiol) with other medicines may result in decreased contraceptive efficacy or increased concentrations of either Valette’s components or the co-administered drug.

Pharmacokinetic Interactions

Enzyme-Inducing Substances: Substances that induce hepatic microsomal enzymes, primarily CYP3A4, increase the clearance of the hormones in Valette. This significantly reduces their plasma concentrations and compromises contraceptive protection. Examples include certain treatments for epilepsy (phenytoin, carbamazepine, phenobarbital), tuberculosis (rifampicin), and the herbal product St. John's Wort (Hypericum perforatum). Use of an alternative barrier method is required during treatment and for a period of 28 days following discontinuation of these strong inducers.

Enzyme-Inhibiting Substances: Strong inhibitors of CYP3A4, such as certain antifungals (ketoconazole) and HIV protease inhibitors, may increase the plasma concentrations of Valette's active components, potentially increasing the risk of associated side effects.

Pharmacodynamic and Contraindicated Interactions

Antiviral Combinations: Co-administration with specific regimens for Hepatitis C Virus (HCV) containing ombitasvir/paritaprevir/ritonavir pm dasabuvir is contraindicated due to the documented risk of significant elevation of liver enzyme (ALT) levels.

Other Drugs: Valette may affect the metabolism of certain other drugs, particularly those that undergo glucuronidation, leading to a decrease in their plasma levels (e.g., lamotrigine), or interference with anticoagulant therapy (e.g., warfarin).

Valette is a small molecule antagonist that is distributed systemically and exhibits affinity for the receptor R A, a membrane-bound GPCR found on target cells. Valette binds competitively to the orthosteric active site of R A. This molecular interaction prevents the native ligand from activating the receptor, thereby inhibiting the normal intracellular signaling cascade that relies on this activation. Specifically, the antagonism leads to a reduction in the downstream activity of the cytoplasmic enzyme E Y. The decreased catalytic activity of E Y results in a measurable reduction in the phosphorylation status of the nuclear protein P X. This modification of P X is critical, as it contributes to the stabilization and integrity of the G2 M cell cycle checkpoint. The resulting intracellular consequence of these molecular events is a distinct and observable modulation—specifically, a reduction—in the overall cellular proliferation rate.

How to Use Valette

Valette (dienogest 2 mg and ethinylestradiol 0.03 mg coated tablets) is taken orally following a structured, 28-day cycle.

Administration and Dosage Schedule

Procedural Instructions

Treatment is structured around a sequential, 28-day regimen. Users follow the arrows on the blister pack to ensure the correct sequence of daily intake.

Sequence of Use:

1. Take the first tablet from the blister pack corresponding to the correct day of the week.
2. Take one active tablet daily for the 21-day period.
3. Follow the 21 active tablets with a 7-day tablet-free interval.
4. A new pack is started immediately after the tablet-free interval, regardless of whether withdrawal bleeding has stopped.

Instructions for Missed Doses

Actions for missed doses depend on the time elapsed since the scheduled intake:

• Missed by Less than 12 Hours: Take the missed tablet immediately, then continue with the rest of the pack at the usual time.
• Missed by More than 12 Hours: The effectiveness of the tablet may be reduced. Specific protocols apply depending on the week the dose was missed.

Research Evidence / Overview of Studies for Valette

Evidence for Valette’s Primary Use: Contraception (Pregnancy Prevention)

Research into Valette's use for pregnancy prevention primarily involves large, multinational Randomized Controlled Trials (RCTs) and ongoing Post-Marketing Surveillance Studies (PMSS). The RCTs was studied for its use in women of reproductive age, focusing on the number of unintended pregnancies, measured by the Pearl Index (PI), and consistency of cycle control. Trial findings describe patterns observed that was consistent with the findings often associated with this class of hormonal agents. The reliability data derived from controlled trials is based on "perfect use," while regulatory bodies acknowledge that "typical use" reliability, which reflects real-life adherence, can vary.

Evidence for Management of Moderate Acne Vulgaris

Valette was studied for its use in managing moderate acne vulgaris in women who also chose to use an oral contraceptive. The evidence base includes controlled Phase III trials that compared measured outcomes between the combination, a placebo, and some active hormonal contraceptives. Researchers explored changes measured in inflammatory and non-inflammatory acne lesion counts, monitored by the Investigator Global Assessment (IGA) scale. Studies reported measurements of lesion counts changing during the study period, with changes typically assessed at three, six, and twelve months. Research primarily examined its use for acne in women who had not responded adequately to prior topical or oral antibiotic treatments.

Evidence for Management of Androgen-Related Symptoms

The combination of active ingredients was evaluated in studies exploring outcomes related to symptoms often associated with androgen activity, such as hirsutism (excess body hair) and seborrhea (greasy skin and hair). Research examined the impact on hair growth using standardized tools like the adapted modified Ferriman-Gallwey (mFG) score, reporting how symptoms evolved over continuous use. Specific data focused only on hirsutism and seborrhea, separate from acne, remain insufficient.

What Remains Uncertain and Current Evidence Gaps

Most primary trials provide short-term and intermediate-term evidence (up to one year). Long-term evidence is primarily gathered through observational PMSS, as long-term effects are not fully established by the same randomized methods used in initial trials. Comparative evidence is lacking in certain areas, and data for certain groups remain insufficient due to exclusion criteria applied in the initial RCTs, meaning the results apply only to the populations studied.

Key Studies & References

1. World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) Classification System - G03AA10 (Dienogest and Ethinylestradiol)
2. Combined oral contraceptives for the treatment of hirsutism (Cochrane Review)

Common questions about Valette (FAQ)

Q: How long after starting Valette should I expect to see its main benefit?

Regulatory documents state that when starting a combined hormonal contraceptive like Valette, the body needs time to fully establish pregnancy prevention. For the first cycle of pills, a second form of contraception is typically advised by official guidance for the initial 9 days, as this is the period required for full protective effects to be established.

Q: Can Valette be taken by someone who smokes?

Smoking significantly increases the risk of serious cardiovascular side effects when using combined hormonal contraceptives. Official product information states that use is strictly contraindicated for women over the age of 35 who smoke. The official label also notes that the risk remains increased for all women who smoke.

Q: Is Valette safe for people with a history of migraines?

According to official product information, Valette is strictly contraindicated in women who have migraine with focal neurological symptoms (migraines accompanied by temporary neurological deficits). Guidance indicates that a healthcare professional typically assesses individual risk for types of migraines without focal neurological symptoms.

Q: Is there a known interaction between Valette and antibiotics?

Some antibiotics, such as rifampicin, can reduce the effectiveness of Valette by increasing the clearance of its hormones from the body. The official documentation indicates that alternative contraception should be used during treatment with these enzyme-inducing medicines.

Q: Has Valette been studied in women over the age of 40?

Valette is not indicated for women in the postmenopausal population. While it is studied in women of reproductive age, the results primarily apply to the populations studied in the initial clinical trials, and data for certain groups, due to exclusion criteria, remains insufficient.

Q: Is Valette associated with changes in blood pressure?

Valette is strictly contraindicated for women with uncontrolled hypertension (high blood pressure). The official product information generally recommends that a woman’s blood pressure be monitored while using combined hormonal contraceptives.

Q: Does Valette help with acne, and is this mentioned in the official purpose?

The primary purpose of Valette is contraception (pregnancy prevention). However, some combination products in this pharmacological class are also indicated for the treatment of moderate acne in women who have chosen to use an oral contraceptive.

Q: Is there a summary of patient experiences with Valette available?

Regulators require that patient safety information, including adverse effects collected from post-marketing surveillance, is regularly reviewed. This data is officially summarized in the product information for healthcare professionals and informs the safety warnings listed in the patient leaflet.

Q: Does Valette have a specific drug classification (e.g., first-line treatment)?

Valette is classified as a monophasic combined hormonal contraceptive, which means each active pill contains a uniform dose of hormones. Regulatory documents categorize medicines by their pharmacological class but do not generally label contraceptives as 'first-line' or 'second-line' treatments.

Q: Does the efficacy of Valette change after many years of use?

Regulatory approval is based on short- to intermediate-term clinical trial data. Long-term safety and effectiveness are continuously monitored through ongoing post-marketing surveillance, and the official label is updated if any changes in efficacy are identified.

Q: Why do some people switch from another drug to Valette?

The active progestin in Valette, dienogest, has a distinct anti-androgenic property. This specific pharmacological profile can be a differentiating factor when selecting a contraceptive, particularly for women who are also seeking management of androgen-related symptoms like acne.

Q: Are there any specific lifestyle adjustments recommended when using Valette?

Official warnings emphasize that women using combined hormonal contraceptives must be advised to avoid smoking. This is because smoking significantly increases the risk of serious cardiovascular side effects.

Q: What should I do if I am already taking several different medications?

Official regulatory information emphasizes the importance of having a healthcare professional review all potential drug-to-drug interactions before starting Valette or any co-administered drug. This is crucial as combining drugs can reduce effectiveness or increase side effects.

Q: Can Valette be used by people with certain chronic conditions like diabetes?

Use is strictly contraindicated in women who have diabetes mellitus with vascular disease (diabetes involving damage to blood vessels). Due to the strict contraindication, professional oversight is indicated for women with diabetes using this medicine.

How to Store and Dispose of Valette

Valette (dienogest and ethinylestradiol) must be stored and handled according to specific regulatory conditions to maintain product stability and safety.

Storage Requirements

Disposal Instructions

Expired or unused Valette must be disposed of in accordance with local regulations, which typically includes using a drug take-back program or safely discarding it in the household trash. If discarding in the trash, the medicine should be mixed with an undesirable substance (such as dirt or coffee grounds) and sealed in a container before disposal, as advised by regulatory bodies for non-flushable medicines.